Skip to main content
. 2019 May 2;4(9):e98101. doi: 10.1172/jci.insight.98101

Figure 8. Solitary administration of bile acid-specific agonists and CBAs does not activate the FXR or TGR5 pathways in the lungs.

Figure 8

(A) Bile acid and vehicle treatment regimen. (B) Gene expression quantified by RT-qPCR from the lungs of mice 24 hours after administration of TUDCA, AβM, INT-747, and INT-777 (or DMSO vehicle control). n = 5 mice per group from 1 experiment. (C) Western blot analysis for phospho-PKA (p-PKA). (D) Densitometry for Western blot in C. Data were analyzed by 1-way ANOVA with Tukey’s post hoc test. *P < 0.05 vs. DMSO control group; ns, not significant vs. DMSO control group (Nr1h4 in TUDCA and HDM plus AβM; Dio2 in TUDCA, AβM, and INT-747; n = 1 outlier each). HK, housekeeping; ns, not significant. Error bars represent ± SEM.